Evidence map›Paper›PMID 37122759›Full record

ArticleFrontiers in immunology2023

Association of gut microbiome and metabolites with onset and treatment response of patients with pemphigus vulgaris.

Yiyi Wang, Xuyang Xia, Xingli Zhou, Tongying Zhan, Qinghong Dai, Yan Zhang, Wei Zhang, Yang Shu, Wei Li, Heng Xu

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
5.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 22 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Yiyi WangDepartment of Dermatology & Rare Disease Center, West China Hospital, Sichuan University, Chengdu, China.
Xuyang XiaState Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Chengdu, China.
Xingli ZhouDepartment of Dermatology & Rare Disease Center, West China Hospital, Sichuan University, Chengdu, China.
Tongying ZhanDepartment of Dermatology & Rare Disease Center, West China Hospital, Sichuan University, Chengdu, China.
Qinghong DaiDepartment of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Xiangya Hospital, Central South University, Changsha, China.
Yan ZhangLung Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Wei ZhangDepartment of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Xiangya Hospital, Central South University, Changsha, China.
Yang ShuState Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Chengdu, China.
Wei LiDepartment of Dermatology & Rare Disease Center, West China Hospital, Sichuan University, Chengdu, China.
Heng XuState Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Chengdu, China.
Sichuan University · CNCentral South University · CNPharmacoGenetics (China) · CNWest China Hospital of Sichuan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Gut dysbiosis and gut microbiome-derived metabolites have been implicated in both disease onset and treatment response, but this has been rarely demonstrated in pemphigus vulgaris (PV). Here, we aim to systematically characterize the gut microbiome to assess the specific microbial species and metabolites associated with PV. Methods: We enrolled 60 PV patients and 19 matched healthy family members, and collected 100 fecal samples (60 treatment-naïve, 21 matched post-treatment, and 19 controls). Metagenomic shotgun sequencing and subsequent quality control/alignment/annotation were performed to assess the composition and microbial species, in order to establish the association between gut microbiome with PV onset and treatment response. In addition, we evaluated short-chain fatty acids (SCFAs) in PV patients through targeted metabolomics analysis. Results: The diversity of the gut microbiome in PV patients deviates from the healthy family members but not between responder and non-responder, or before and after glucocorticoid treatment. However, the relative abundance of several microbial species, including the pathogenic bacteria (e.g., Conclusions: This study supports the association between the gut microbiome and PV onset, possibly through disrupting the balance of gut pathogenic bacteria and probiotics and influencing the level of gut microbiome-derived SCFAs. Furthermore, we revealed the potential relationship between specific microbial species and glucocorticoid treatment.

Indexed as

Gastrointestinal MicrobiomePemphigusBacteriaEubacteriumFatty Acids, VolatileGlucocorticoidsHumansFatty Acids, VolatileGlucocorticoidsglucocorticoidmetagemonicmicrobiomepemphigus vulgarisshort-chain fatty acids

Identifiers

PMID37122759
PMCPMC10140300
OpenAlexW4365516110

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.